Hormone receptor positive breast cancer is a type of breast cancer in which cancer cells contain receptors for estrogen, progesterone, or both. These hormones can contribute to cancer cell growth, making hormone therapy an important part of treatment for many patients. Treatment decisions depend on the cancer stage, tumor characteristics, menopausal status, overall health, and individual preferences.
Hormone receptor positive breast cancer is commonly identified through laboratory testing of a tumor sample. Estrogen receptor positive and progesterone receptor positive cancers may respond to treatments that reduce hormone production or block hormones from stimulating cancer cells. Some tumors are also HER2 positive, which can influence treatment selection. Doctors evaluate these results alongside tumor size, lymph node involvement, cancer stage, and other clinical factors to develop an individualized treatment plan. Treatment may involve one approach or a combination of therapies, depending on the risk of recurrence and whether the cancer is early stage or advanced.
Hormone therapy, also called endocrine therapy, is a central treatment for many hormone receptor positive breast cancers. It works by reducing the body's estrogen production or preventing hormones from activating receptors on cancer cells. Depending on the diagnosis, treatment may begin after surgery or be used to manage cancer that has spread to other parts of the body.
Common treatment approaches include:
Tamoxifen: Blocks estrogen receptors in breast tissue and may be used in premenopausal or postmenopausal patients.
Aromatase inhibitors: Medicines such as anastrozole, letrozole, and exemestane reduce estrogen production and are commonly used after menopause. They may also be used before menopause with ovarian suppression.
Ovarian suppression: Medicines or procedures that reduce ovarian hormone production may be recommended for selected premenopausal patients.
Surgery: Breast-conserving surgery or mastectomy may be considered according to tumor characteristics and patient preferences.
Radiation therapy: May be recommended after breast-conserving surgery and in certain other situations to reduce the risk of cancer returning locally.
Chemotherapy: May be appropriate when clinical features or recurrence-risk assessments indicate that additional treatment is beneficial.
The choice and duration of hormone therapy depend on individual risk factors and treatment goals. Many patients with early-stage disease receive endocrine therapy for at least five years, while some may benefit from a longer course. Treatment duration should be determined with the oncology team.
Some patients require additional treatments based on the tumor's characteristics and the extent of the disease. For example, certain patients with higher-risk early-stage cancer may benefit from targeted medicines, such as CDK4/6 inhibitors, alongside endocrine therapy. Advanced or metastatic hormone receptor positive breast cancer may be treated with endocrine therapy combined with targeted medicines, depending on previous treatments, tumor testing, and other clinical considerations.
Important aspects of treatment and ongoing care include:
Targeted therapy: Medicines such as ribociclib, abemaciclib, or palbociclib may be used in appropriate clinical settings to slow cancer cell growth.
Side effect management: Hormone therapies may cause hot flashes, joint discomfort, vaginal dryness, or changes in bone health. Other medicines can have additional side effects requiring monitoring.
Regular monitoring: Follow up visits help clinicians assess treatment response, manage adverse effects, and review whether the treatment plan remains appropriate.
Bone health: Some endocrine treatments can affect bone density, making exercise, adequate nutrition, and bone health assessments important when recommended.
Personalized decisions: Menopausal status, other health conditions, medication interactions, and patient preferences may influence treatment selection.
Patients should discuss new symptoms, persistent side effects, and concerns about medication with their healthcare team rather than stopping prescribed treatment independently. Follow up schedules and imaging recommendations vary according to the treatment stage and clinical circumstances.
Hormone receptor positive breast cancer can often be managed with a combination of established and newer treatment approaches. The most appropriate plan depends on the individual diagnosis, the likelihood of recurrence, treatment tolerance, and personal circumstances. Working with an oncology team helps patients understand the potential benefits and limitations of available options, make informed treatment decisions, and receive appropriate monitoring throughout care.